$0.16 EPS Expected for AngioDynamics, Inc. (ANGO)

July 3, 2017 - By Migdalia James

 $0.16 EPS Expected for AngioDynamics, Inc. (ANGO)
Investors sentiment increased to 3.16 in Q4 2016. Its up 0.55, from 2.61 in 2016Q3. It increased, as 8 investors sold AngioDynamics, Inc. shares while 23 reduced holdings. 32 funds opened positions while 66 raised stakes. 61.14 million shares or 119.62% more from 27.84 million shares in 2016Q3 were reported.
Parametric Associates Lc holds 0% or 80,871 shares. Pnc Ser Gp owns 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 7,400 shares. 140,276 are owned by Schwab Charles Management. Alliancebernstein L P accumulated 213,650 shares. Metropolitan Life Insur Ny owns 20,495 shares. Aqr Management Ltd Liability Company invested in 0% or 136,911 shares. Menta Cap Ltd Limited Liability Company, California-based fund reported 59,768 shares. Jpmorgan Chase has 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO). Pinebridge L P, New York-based fund reported 34,581 shares. Susquehanna Int Group Limited Liability Partnership has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Nationwide Fund has 114,386 shares. Smith Asset Mgmt Gp Limited Partnership, a Texas-based fund reported 17,570 shares. Profund Limited Company holds 10,060 shares or 0.01% of its portfolio. Acadian Asset Mngmt Lc reported 536,295 shares. Millennium Mgmt Limited Company holds 0.02% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO) for 444,196 shares.

Analysts await AngioDynamics, Inc. (NASDAQ:ANGO) to report earnings on July, 12. They expect $0.16 EPS, down 15.79 % or $0.03 from last year’s $0.19 per share. ANGO’s profit will be $5.83M for 25.33 P/E if the $0.16 EPS becomes a reality. After $0.19 actual EPS reported by AngioDynamics, Inc. for the previous quarter, Wall Street now forecasts -15.79 % negative EPS growth. The stock decreased 1.04% or $0.17 on June 30, reaching $16.21. About shares traded. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 31.47% since July 3, 2016 and is uptrending. It has outperformed by 14.77% the S&P500.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Among 7 analysts covering AngioDynamics (NASDAQ:ANGO), 2 have Buy rating, 0 Sell and 5 Hold. Therefore 29% are positive. AngioDynamics had 10 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was maintained by Canaccord Genuity on Friday, January 8 with “Buy”. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) earned “Sell” rating by Zacks on Monday, August 31. The firm has “Hold” rating by Canaccord Genuity given on Wednesday, May 31. As per Wednesday, February 8, the company rating was initiated by Barclays Capital. On Tuesday, April 5 the stock rating was downgraded by Canaccord Genuity to “Hold”. The rating was reinitiated by Piper Jaffray on Friday, April 8 with “Neutral”. The firm earned “Neutral” rating on Wednesday, September 23 by Sidoti. Raymond James downgraded the shares of ANGO in report on Tuesday, November 10 to “Mkt Perform” rating. As per Friday, November 4, the company rating was initiated by Cantor Fitzgerald. The firm has “Overweight” rating by KeyBanc Capital Markets given on Friday, July 24.

AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The company has market cap of $590.16 million. The Company’s devices are used in minimally invasive, image-guided procedures. It currently has negative earnings. The Firm offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery.

Another recent and important AngioDynamics, Inc. (NASDAQ:ANGO) news was published by Seekingalpha.com which published an article titled: “AngioDynamics announces FDA clearance for the Solero MTA System” on June 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: